Multifocal motor neuropathy
disease diseaseOn this page
Also known as MMNMMNCBmultifocal motor neuropathy with conduction block
Summary
Multifocal motor neuropathy (MONDO:0018979) is a disease and 20 clinical trials. Top therapeutic interventions include human immunoglobulin g, hyaluronidase (human recombinant), and empasiprubart. A subtype of acquired peripheral neuropathy — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Prevalence: 1-9 / 100 000 (Worldwide) [Orphanet-validated]
- Phenotypes (HPO): 12
- Clinical trials: 20
Clinical features
Epidemiology
Prevalence records
2 prevalence record(s), Orphanet:
| Type | Class | Value | Geography | Validation |
|---|---|---|---|---|
| Point prevalence | 1-9 / 100 000 | 1.5 | Worldwide | Validated |
| Point prevalence | 1-9 / 1 000 000 | 0.16 | Japan | Validated |
Signs & symptoms
Clinical features (HPO)
12 HPO clinical features (Orphanet curated; top 12 by frequency):
| HPO ID | Term | Frequency |
|---|---|---|
| HP:0009063 | Progressive distal muscle weakness | Very frequent (80-99%) |
| HP:0001315 | Reduced tendon reflexes | Frequent (30-79%) |
| HP:0002380 | Fasciculations | Frequent (30-79%) |
| HP:0002922 | Increased CSF protein concentration | Frequent (30-79%) |
| HP:0003323 | Progressive muscle weakness | Frequent (30-79%) |
| HP:0003394 | Muscle spasm | Frequent (30-79%) |
| HP:0003690 | Limb muscle weakness | Frequent (30-79%) |
| HP:0004302 | Functional motor deficit | Frequent (30-79%) |
| HP:0004345 | Abnormality of ganglioside metabolism | Frequent (30-79%) |
| HP:0006251 | Limited wrist extension | Frequent (30-79%) |
| HP:0009077 | Weakness of long finger extensor muscles | Frequent (30-79%) |
| HP:0012078 | Motor conduction block | Frequent (30-79%) |
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | multifocal motor neuropathy |
| Mondo ID | MONDO:0018979 |
| Orphanet | 641 |
| ICD-10-CM | G61.82 |
| SNOMED CT | 230591002 |
| UMLS | C0393847 |
| MedGen | 581615 |
| GARD | 0011011 |
| NORD | 1952 |
| Is cancer (heuristic) | no |
Also known as: MMN · MMNCB · multifocal motor neuropathy with conduction block
Disease family
Classification path: disease › human disease › disease by body system or component › nervous system disorder › peripheral nervous system disorder › peripheral neuropathy › acquired peripheral neuropathy › multifocal motor neuropathy
Related subtypes (11): axonal polyneuropathy associated with IgG/IgM/IgA monoclonal gammopathy, cranial neuralgia, neuralgic amyotrophy, POEMS syndrome, non-recovering obstetric brachial plexus lesion, anterior cutaneous nerve entrapment syndrome, pudendal neuralgia, polyneuropathy associated with IgM monoclonal gammapathy with anti-MAG, CANOMAD syndrome, simple cryoglobulinemia, radiation-induced plexopathy
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 20.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 9 |
| PHASE2 | 6 |
| PHASE3 | 4 |
| PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT05084053 | PHASE3 | ACTIVE_NOT_RECRUITING | A Study of TAK-771 in Japanese Participants With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) and Multifocal Motor Neuropathy (MMN) |
| NCT06742190 | PHASE3 | ACTIVE_NOT_RECRUITING | A Study to Assess the Efficacy and Safety of Empasiprubart Versus IVIg in Adults With Multifocal Motor Neuropathy |
| NCT00666263 | PHASE3 | COMPLETED | Study of the Effectiveness of Intravenous Immune Globulin (10%) for the Treatment of Multifocal Motor Neuropathy |
| NCT01827072 | PHASE3 | COMPLETED | Phase III Clinical Trial of NPB-01maintenance Therapy in Patients With Multifocal Motor Neuropathy. |
| NCT05405361 | PHASE2 | ACTIVE_NOT_RECRUITING | A Clinical Trial to Investigate the Long-term Safety and Tolerability, Efficacy, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of ARGX-117 in Adults With Multifocal Motor Neuropathy |
| NCT06537999 | PHASE2 | RECRUITING | A Clinical Study to Evaluate DNTH103 in Adults With Multifocal Motor Neuropathy |
| NCT00268788 | PHASE2 | COMPLETED | Subcutaneous Immunoglobulin Treatment for Multifocal Motor Neuropathy |
| NCT00701662 | PHASE2 | COMPLETED | A Study of Purified Human Antibodies Administered Subcutaneously to Patients With Multifocal Motor Neuropathy (MMN) |
| NCT02556437 | PHASE2 | COMPLETED | Efficacy and Safety of HyQvia (Immunoglobulin 10% With Recombinant Hyaluronidase) in Multifocal Motor Neuropathy (MMN) |
| NCT05225675 | PHASE2 | COMPLETED | A Clinical Trial to Investigate the Safety and Tolerability, Efficacy, Pharmacokinetics, Pharmacodynamics and Immunogenicity of 2 Dose Regimens of ARGX-117 in Adults With Multifocal Motor Neuropathy |
| NCT07610564 | PHASE1 | NOT_YET_RECRUITING | A Study to Assess the Effect of Empasiprubart on Nerve Morphology by Ultrasound in Adults With Multifocal Motor Neuropathy |
| NCT05988073 | Not specified | ACTIVE_NOT_RECRUITING | A Prospective Longitudinal Study in Adults With Multifocal Motor Neuropathy |
| NCT06040567 | Not specified | RECRUITING | Polyneuropathy, Impairments and Physical Activity - The PolyImPAct Study |
| NCT01655394 | Not specified | UNKNOWN | Change of Nerve Conduction Properties in IVIg Dependent Neuropathies |
| NCT02111590 | Not specified | COMPLETED | Immunoglobulin Dosage and Administration Form in CIDP and MMN |
| NCT02121678 | Not specified | COMPLETED | Effect of Resistance and Aerobic Exercise in CIDP or MMN |
| NCT02885259 | Not specified | UNKNOWN | HyQvia in Multifocal Motor Neuropathy |
| NCT04015934 | Not specified | COMPLETED | Predictive Factors of Long Term Outcome in MMN |
| NCT04356781 | Not specified | COMPLETED | Do IgG Level Variations in CIDP and MMN Patients Following Initial Intravenous IVIg Treatment Correlate With Ultimate Dosing |
| NCT04614792 | Not specified | COMPLETED | Excitatory Prefrontal Weak Current Stimulation in Vegetative Patients |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| HUMAN IMMUNOGLOBULIN G | 4 | 2 |
| HYALURONIDASE (HUMAN RECOMBINANT) | 4 | 1 |
| EMPASIPRUBART | 2 | 3 |